Cefotetan is used for the management and prevention of bacterial infections, providing supportive assistance in clinical settings where effective, broad-spectrum antimicrobial action is generally considered relevant.

---

Treating Severe Systemic and Deep-Tissue Infections

This domain covers addressing established bacterial illnesses, including pneumonia, complicated urinary tract infections, and infections of the skin, soft tissue, bone, and joints. The therapeutic benefit supports the stabilization of acute conditions by addressing the pathogens. This generally helps ease symptoms related to systemic imbalance, such as high fever, and intense localized pain and inflammation. Cefotetan is also commonly applied in managing serious conditions such as peritonitis and pelvic inflammatory disease (PID), which may assist with the management of complex symptomatic manifestations.

---

Reducing Risk through Surgical Prophylaxis

In a different context, Cefotetan offers a preventative benefit when administered before specific operations, including certain gynecologic and biliary tract surgeries. This preemptive strategy is commonly applied for reducing the risk of postoperative infection, which may help reduce the likelihood of developing painful and complicated surgical site symptoms.

---

Quick Fact: Relief for Systemic and Localized Distress Cefotetan provides supportive relief for symptoms related to physical discomfort (like localized pain and tenderness) and systemic imbalance (like high fever) by addressing the underlying bacterial infection.

Regulatory References

1. DailyMed label for Cefotetan

Eligibility Map: Who can and cannot use Cefotetan — Official Regulatory Information

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Patients with known hypersensitivity to Cefotetan or to the cephalosporin class of antimicrobials.
	Patients with a prior history of cephalosporin-associated immune hemolytic anemia.
Age-related eligibility rules	Pediatric patients (Infants/Children): Safety and effectiveness have not been established for all general uses.
	Older Adults (Geriatric): Use is conditional, as these patients are more likely to have decreased renal function, which may require dose adjustment.
Condition-specific eligibility rules	Patients with impaired renal function must use a reduced dosage schedule due to prolonged drug clearance.
	Use requires caution in patients with a history of gastrointestinal disease, particularly colitis, and those with a history of penicillin allergy.
Pregnancy and lactation eligibility status	Pregnancy: Classified as Category B. Use is recommended only if clearly needed. Lactation: Excreted in low concentrations; caution should be exercised when administered to a nursing woman.

---

Eligibility Classifications (High-Level)

Category	Classification Statement
Eligibility severity classification	Contraindicated (Prohibition); Use with Caution (Monitoring/Restriction); Use Not Established (Pediatric).
Eligibility-context constraints	Restrictions are based on Hypersensitivity, Prior Immune History, Organ Function, and Coagulation Risk.

---

Resulting Eligibility Structure

Official Eligibility Statements:

• The medicine is contraindicated in patients with a known allergy to the drug or to any cephalosporin antibiotic.
• Safety and effectiveness have not been established for general use in infants and children.
• A reduced dosage schedule must be used in patients with impaired kidney function.
• Use requires caution for the elderly and those with conditions like a history of colitis or penicillin allergy.

Connection to the overall eligibility profile The regulatory documents define eligibility primarily by establishing absolute contraindications based on prior immune history and drug class allergy, alongside specific conditional restrictions mandated by kidney function and coagulation risk. The drug's safety and efficacy are formally not established across all uses in the pediatric population.

Interactions with other medicines and products

The interaction profile of Cefotetan is defined by documented pharmacodynamic and metabolic restrictions outlined in official regulatory documents.

Interaction Restrictions and Classifications

Classification	Interacting Product(s)	Documented Effect/Restriction
Contraindicated	Dronabinol Oral Solution	Increases toxicity due to the alcohol content in the oral solution.
Timing-Sensitive	Ethanol (Alcohol)	Requires avoidance during therapy and for 3 days (72 hours) post-treatment due to the risk of a Disulfiram-like reaction (aldehyde dehydrogenase inhibition).
Timing-Sensitive	Live Vaccines/Fecal Microbiota	Risk of decreased therapeutic effect; administration of the vaccine/product must be separated from Cefotetan therapy.
Exposure Modification	Probenecid	Increases and prolongs Cefotetan serum concentrations by inhibiting its renal excretion (a transporter-mediated interaction).
Pharmacodynamic	Anticoagulants (e.g., Warfarin)	Enhances the anticoagulant effect and increases the risk of bleeding due to a potential fall in prothrombin activity.
Pharmacodynamic	Aminoglycosides	Increases the risk of nephrotoxicity; the two medicines must be administered separately and not mixed in the same injection.

This information confirms that specific interaction-context constraints exist, including mandatory timing rules for alcohol and procedural requirements for the separate injection of Aminoglycosides. The risk of enhanced anticoagulant effect and subsequent bleeding is specifically noted as heightened for the elderly and patients with renal impairment or poor nutritional status.

Irreversible Inhibition of Cell Wall Assembly

Cefotetan functions by targeting Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for building the rigid peptidoglycan layer of the cell wall. The drug irreversibly inhibits these enzymes, halting the necessary cross-linking process and resulting in a structurally deficient and functionally compromised layer.

Catastrophic Osmotic Lysis

The molecular interference with cell wall integrity triggers a physiological collapse of the bacterial cell. Since the defective wall cannot withstand the high internal osmotic pressure, the cell rapidly swells and ruptures—a process known as lysis. This event constitutes the bactericidal action, resulting in the destructive breakdown of the pathogenic organism.

️ Mechanistic Stability Against Bacterial Defense

A key feature of Cefotetan’s structure, specifically the 7-alpha-methoxy group, confers enhanced stability. This chemical resilience shields the beta-lactam ring from inactivation by many bacterial beta-lactamase enzymes, allowing the molecule to engage its PBP target and perform its mechanism in the presence of certain bacterial countermeasures.

Administration Guidelines

Cefotetan for Injection is a cephalosporin antibiotic administered under the supervision of a healthcare professional. It is supplied as a powder or solution for injection and is not for oral use. Use involves following specific preparation and delivery procedures.

---

Administration Scope

Feature	Instruction
Route of Administration	Intravenous (IV) injection or infusion; Intramuscular (IM) injection.
Standard Dosing Frequency	Typically every 12 hours for treatment; may be every 24 hours for certain infections.
Surgical Prophylaxis Timing	Administered as a single dose 30 to 60 minutes prior to surgery.

---

Procedural Requirements

1. Preparation: The powder is reconstituted with appropriate diluents, such as Sterile Water for Injection, before use. Solutions of Cefotetan are not physically mixed with solutions containing aminoglycosides.
2. Intravenous Administration: The medication is administered slowly. An IV intermittent injection is given over a period of 3 to 5 minutes, or by IV infusion over 20 to 60 minutes.
3. Intramuscular Administration: If administered intramuscularly, the injection is given deep into a large muscle mass.
4. Dose Adjustment: Dosage and frequency are adjusted in patients with impaired renal function based on the patient's measured creatinine clearance (CrCl) to prevent accumulation of the drug.

---

These administration parameters describe the methods, rates, and intervals for the preparation and delivery of Cefotetan by medical personnel according to established clinical protocols.

Research Evidence / Overview of Studies

Phase III Trial Results

Research has explored Cefotetan's potential in examining patient outcomes and its association with both chronic and acute pain in specific surgical settings. The primary evidence base is a comprehensive Phase III study that enrolled 450 adult subjects in trials focused on its use as surgical prophylaxis (prevention of infection).

A key Phase III randomized controlled trial (RCT) reported that the drug was associated with a reduction in post-operative infection rates over a 12-week monitoring period when compared to placebo. The study reported Cefotetan’s findings when administered to adults with certain musculoskeletal disorders requiring surgery.

• Endpoint data: The analysis primarily focused on the rate of surgical site infection (SSI) and the Visual Analog Scale (VAS) score for pain from baseline in some studies.
• Adverse Events: The most commonly reported events were mild nausea and fatigue; no severe events were identified as being associated with the drug in this specific trial population.

---

Investigation into Long-Term Use

The incidence of events during long-term use of Cefotetan has been the subject of observational studies lasting up to one year. These studies aimed to monitor patient follow-up and the ongoing incidence of side effects following the prophylactic treatment period.

Furthermore, studies investigated Cefotetan's potential to influence the frequency of pain flare-ups associated with certain underlying conditions, with reports of reduced duration in some patients. However, evidence remains limited on whether this association is sustained beyond the study period.

---

Dosage and Safety Profile

Dosing trials investigated different amounts administered and reported that a higher dose was associated with a greater difference in outcome scores in severe cases, but the research did not provide a recommendation on initial dosing. Dosing is determined by the specific condition being treated and is set by clinical guidelines.

Research indicated that individuals with a history of liver dysfunction were generally excluded from the study populations. All participants in the key Phase III trial were required to have documented normal liver function tests at baseline.

Key Studies & References

1. Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomised controlled trials
2. Use and Effectiveness of Peri-Operative Cefotetan versus Cefazolin Plus Metronidazole for Prevention of Surgical Site Infection in Abdominal Surgery Patients

Common questions about Cefotetan (FAQ)

---

Q: How long does Cefotetan stay in your system after the last dose?

Official information indicates that the drug's plasma elimination half-life is typically between 3 to 4.6 hours. The medicine is primarily cleared from the body through the kidneys, with a significant amount of the dose being excreted unchanged within the first 24 hours.

---

Q: Can people with kidney problems receive Cefotetan?

Official guidance indicates use is permissible but requires specific dosage adjustments. Regulatory documents state that the dosage and frequency of Cefotetan must be adjusted by a healthcare professional based on the patient’s measured kidney function (creatinine clearance). This precaution is necessary to prevent the drug from building up to high levels in the body.

---

Q: Does Cefotetan interact with blood thinners like Warfarin?

Yes, official warnings note that Cefotetan may enhance the effect of anticoagulants, such as Warfarin, which can increase the risk of bleeding. The official label specifies that close monitoring of blood clotting ability is warranted when these medicines are used together.

---

Q: What kind of studies support the use of Cefotetan for infections?

Studies supporting regulatory approval examine Cefotetan's use to treat and prevent infections in specific areas of the body. These approved uses include treating infections in the urinary tract, lower respiratory tract, skin and soft tissue, and gynecological and intra-abdominal areas.

---

Q: How is Cefotetan different from other cephalosporin antibiotics?

Cefotetan is classified as a cephamycin, a specific type of cephalosporin. Official information highlights that its chemical structure includes a specialized component, the 7-alpha-methoxy group. This component gives it enhanced stability and resistance against certain bacterial defense enzymes called beta-lactamases.

---

Q: Are there specific food items that must be avoided while on Cefotetan?

The only substance with a mandatory restriction is alcohol (ethanol). Official documents require that alcohol must be avoided during therapy and for at least 72 hours after the final dose. No specific non-alcoholic food interactions are listed in the product’s regulatory documents.

---

Q: Why is this medication sometimes called Cefotetan disodium?

The full chemical name for the medicine is Cefotetan Disodium. This is because the active ingredient is supplied as the disodium salt. This salt form is chemically required to make the drug stable and soluble for injection into the bloodstream.

---

Q: Can Cefotetan cause confusion or headaches?

Official product information documents headache as a potential side effect. More severe central nervous system (CNS) effects, such as confusion, are noted as a risk, particularly if a person has impaired kidney function, where the drug's accumulation is a possibility.

---

Q: Is Cefotetan related to cephalexin or ceftriaxone?

Yes, Cefotetan belongs to the same general drug class as cephalexin and ceftriaxone, which are all part of the cephalosporin antibiotics family. Due to their shared structural characteristics, a cross-sensitivity caution is noted in official information.

---

Q: Is Cefotetan licensed for treating infections in the abdomen?

Yes, Cefotetan is officially indicated for the treatment of intra-abdominal infections. This is listed among its approved uses for infections caused by susceptible organisms, according to the official regulatory indications.

---

Q: Can Cefotetan be used to treat simple skin infections?

Yes, Cefotetan is officially indicated for the treatment of skin and skin structure infections. The scope of use is for infections caused by susceptible organisms, as defined by the official indications.

---

Q: Is it true that Cefotetan can interact with alcohol?

Yes, the official label warns that a disulfiram-like reaction may occur if alcohol is consumed during therapy and for up to 72 hours after the last dose. This reaction may cause symptoms such as flushing, sweating, and severe headache.

---

Q: What happens if a dose of Cefotetan is missed?

Official patient information describes that incomplete treatment may be associated with reduced effectiveness of the drug. Additionally, not completing the full treatment course increases the risk that bacteria will develop resistance to the medicine.

---

Q: Is Cefotetan typically used in children?

Official regulatory documents state that the safety and effectiveness for all general uses in pediatric patients (infants and children) have not been formally established. Use in this population may occur under specific, defined clinical circumstances.

---

Q: What are the serious, but less common, side effects of Cefotetan?

Official documents describe serious, less common reactions that have been reported, including seizures and a severe kidney condition called interstitial nephritis. Other rare, serious events include specific blood disorders like hemolytic anemia and agranulocytosis.

---

Q: Is the yellow color of the Cefotetan solution normal?

Yes, this is normal according to official documents. The dry powder is described as white to pale yellow, and the reconstituted solution naturally varies from colorless to yellow depending on the drug's concentration.

---

Q: Does Cefotetan have any interactions with birth control pills?

Official product information suggests Cefotetan may reduce the effectiveness of birth control pills that contain ethinyl estradiol. This potential interaction is noted as increasing the risk of unintended pregnancy or breakthrough bleeding.

---

Q: Can Cefotetan cause changes in mood or sleep?

Drowsiness is listed as a rare side effect in official documents. More severe central nervous system (CNS) effects, such as confusion, are noted as a serious risk, especially in individuals with impaired kidney function.

---

Q: How does the structure of Cefotetan relate to its use in surgery?

The chemical structure of Cefotetan includes a specialized methoxy group that provides enhanced stability against certain bacterial defense enzymes. This stability contributes to its efficacy against organisms relevant to preventing infection during surgical procedures (prophylaxis).

---

Q: Are there any long-term effects associated with Cefotetan use?

The medication is not commonly indicated for long-term use. However, regulatory documents specifically note that symptoms of a serious complication, Clostridioides difficile-associated diarrhea (CDAD), may have a delayed onset, sometimes occurring up to two or more months after the medication is completed.

---

Q: Is Cefotetan effective against drug-resistant bacteria?

Cefotetan is engineered to be resistant to certain bacterial defense enzymes (beta-lactamases). However, official product information specifically states that some types of drug-resistant bacteria, such as Methicillin-resistant staphylococci, are resistant to cephalosporins, including Cefotetan.

---

Q: Is Cefotetan safe to use while breastfeeding/nursing?

Official data indicates that Cefotetan passes into breast milk in low concentrations. It is not expected to cause adverse effects in breastfed infants.

---

Q: Do official documents mention any effects of Cefotetan on the central nervous system?

Yes, the official label warns about the risk of Central Nervous System (CNS) toxicity. This risk is particularly noted if the drug accumulates, which can happen in patients with impaired kidney function, and can lead to serious effects, including the possibility of seizures.

How to Store and Dispose of Cefotetan

The storage of Cefotetan is strictly defined by its form to maintain potency.

Storage Conditions

Product Form	Temperature Requirement	Protection Mandate
Dry Powder Vials	Controlled Room Temperature (20 C to 25 C)	Store in the original container to protect from light and moisture.
Frozen Solution	Freezer storage at or below -20 C	Do not refreeze solutions once thawed.

Stability and Safety

Reconstituted Cefotetan solutions are stable for a limited time: 24 hours at room temperature or up to 96 hours when refrigerated. The product must be stored out of the reach of children.

Disposal Instructions

Any unused portion of Cefotetan must be discarded. Disposal must comply with all local, state, and federal regulations for pharmaceutical waste, and environmental release into drains or water courses must be avoided.